hVIVO plc (Ticker: HVO) is a science led drug development partner purpose-built to meet the growing complexity of modern clinical research. The Company operates an integrated end-to-end ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.
The NIHR:
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The Science Behind specialise in integrating cutting-edge non-invasive neurostimulation and neuroimaging technologies and services to enhance Phase I clinical trials.
Innovatively applying techniques such as transcranial magnetic stimulation (TMS), quantitative sensory testing (QST) and electroencephalography (EEG), either independently or in combination with cognitive or physiological assessments, The Science Behind excels in addressing crucial questions related to target engagement, dose response and the timing of efficacy.
Our approach provides information on how a drug impacts various aspects of central nervous system function. This deeper insight into the neural mechanisms of drug action in humans serves to guide the development of new treatments, potentially enhancing their prospects for success in future clinical trials.
